The FLOW trial, a dedicated renal outcome study, found that semaglutide significantly slowed kidney function decline in T2D patients with CKD (the trial was stopped early for efficacy)—underscoring the kidney-protective role of GLP-1 RAs [191]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.